p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

Krayem, Mohammad; Journe, Fabrice; Wiedig, Murielle; Morandini, Renato; Najem, Ahmad; Salès, François; van Kempen, Leon C; Sibille, Catherine; Awada, Ahmad; Marine, Jean-Christophe; Ghanem, Ghanem

Krayem, Mohammad; Journe, Fabrice; Wiedig, Murielle; Morandini, Renato; Najem, Ahmad; Salès, François; van Kempen, Leon C; Sibille, Catherine; Awada, Ahmad; Marine, Jean-Christophe; Ghanem, Ghanem.

Affiliation

Krayem M; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Journe F; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Wiedig M; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Morandini R; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Najem A; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Salès F; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
van Kempen LC; Department of Pathology, McGill University and Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, H3T 1E2 Montreal, QC, Canada.
Sibille C; Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Awada A; Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Marine JC; Laboratory for Molecular Cancer Biology, Center for Human Genetics, KUleuven, Leuven, Belgium; Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, VIB-KULeuven, Belgium.
Ghanem G; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: gghanem@ulb.ac.be.

Eur J Cancer ; 55: 98-110, 2016 Mar.

Article in En | MEDLINE | ID: mdl-26790143

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Indoles/pharmacology; Melanoma/drug therapy; Protein Kinase Inhibitors/pharmacology; Proto-Oncogene Proteins B-raf/antagonists & inhibitors; Quinuclidines/pharmacology; Skin Neoplasms/drug therapy; Sulfonamides/pharmacology; Tumor Suppressor Protein p53/metabolism; Animals; Apoptosis/drug effects; Cell Line, Tumor; Cell Proliferation/drug effects; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Predisposition to Disease; Humans; Male; Melanoma/enzymology; Melanoma/genetics; Melanoma/pathology; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinase/metabolism; Proto-Oncogene Proteins B-raf/genetics; Proto-Oncogene Proteins B-raf/metabolism; Proto-Oncogene Proteins c-akt/metabolism; Signal Transduction/drug effects; Skin Neoplasms/enzymology; Skin Neoplasms/genetics; Skin Neoplasms/pathology; Time Factors; Tumor Suppressor Protein p53/genetics; Vemurafenib; Xenograft Model Antitumor Assays

Key words

(V600E/K)BRAF; Drug resistance; Melanoma; PRIMA-1(Met); Vemurafenib; p53

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinuclidines / Skin Neoplasms / Sulfonamides / Antineoplastic Combined Chemotherapy Protocols / Tumor Suppressor Protein p53 / Proto-Oncogene Proteins B-raf / Protein Kinase Inhibitors / Indoles / Melanoma Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Eur J Cancer Year: 2016 Type: Article Affiliation country: Belgium

Fulltext

XML

PubMed Links

Search on Google